Interdisciplinary Neurosurgery (Mar 2021)

Prognostic significance of L-type amino acid transporter-1 (LAT-1) expression in human astrocytic gliomas

  • Ahmad Faried, MD., PhD,
  • Hendrikus M.B. Bolly, MD., PhD,
  • Yulius Hermanto, MD., PhD,
  • Arifudin Achmad, MD., PhD,
  • Danny Halim, MD., PhD,
  • Firman P. Tjahjono, MD., MSc,
  • Hasrayati Agustina, MD., PhD,
  • Achmad H.S. Kartamihardja, MD., PhD,
  • Muhammad Z. Arifin, MD., PhD

Journal volume & issue
Vol. 23
p. 100939

Abstract

Read online

Background: Gliomas are the most prevalent type of primary brain tumors. Clarifying the correlation between glioma markers and disease progression provide a basis for adjuvant treatments. We examined Isocitrate dehydrogenase 1 (IDH1) expression, Ki-67, programmed death-ligand 1 (PD-L1) and L-type amino acid transporter 1 (LAT-1) with respect to overall survival in glioma patients. Methods: Immunohistochemistry (IHC) results from 25 glioma samples were analyzed semi-quantitatively. By WHO criteria, eleven specimens were diagnosed as grade II, 7 as grade III, and 7 as grade IV. Grade II was classified as lower grade glioma (LGG); grade III-IV were classified as high grade glioma (HGG). Results: In this study, immuno-characterization revealed HGG was associated with high Ki-67, PD-L1, and LAT-1 expression (p < 0.05), but not with IDH1 R132H mutant expression (p = 0.6217). Both LAT-1 and PD-L1 were associated with Ki-67 expression (p < 0.05). LAT-1 was found to be correlated with PD-L1 expression (r = 0.525, p = 0.007). Upon, multivariate analysis, LAT-1 expression in human astrocytic gliomas was meaningful as an independent prognosis factor (HR = 0.004 (0.00004–0.41)). Conclusion: LAT-1 and PD-L1 expression by HGG contribute to the disease progression. LAT-1 expression in astrocytic gliomas serves an independent prognosis factor. Therefore, LAT-1 and PD-L1 examination is potentially valuable diagnostic markers for adjuvant therapies.

Keywords